Fund | Reference index | |
---|---|---|
1 month | ||
3 months | ||
YTD | ||
1 year | ||
2 years | ||
3 years | ||
5 years | ||
10 years | ||
{{'fund.detail.performance.period.sinceInception' | labelize:[ fundDate(fund.fundPerformances.sinceStart.startDate,'MM-YYYY') ]}} |
Fund | Reference index | |
---|---|---|
Based on transaction prices, the fund's return was 15.28%. Robeco BP US Premium Equities outperformed the Russell 3000 Value Index in November, with stock selection and sector allocation both adding strongly to performance. From a stock selection perspective, healthcare and energy added most value. In healthcare, top ten holding McKesson soared over 22%, while avoiding some of the more expensive names, such as Danaher and Becton Dickinson, helped. Within energy, positions in oil and gas companies including Diamondback Energy and Cimarex Energy benefited most from the market's anticipation of the full ‘reopening’ that would come with a Covid vaccine. From a sector allocation perspective, underweight exposure to the ‘expensive’ utilities and consumer staples sectors was additive during the month.
3 years | 5 years | ||
---|---|---|---|
Tracking error ex-post (%) |
|
||
Information ratio | |||
Sharpe ratio | |||
Alpha (%) | |||
Beta |
|
||
Standard deviation |
|
||
Max. monthly gain (%) |
|
||
Max. monthly loss (%) |
|
3 years | 5 years | ||
---|---|---|---|
Months outperformance | |||
Hit ratio (%) | |||
Months Bull market | |||
Months outperformance Bull | |||
Hit ratio Bull (%) | |||
Months Bear market | |||
Months outperformance Bear | |||
Hit ratio Bear (%) |
Fund | Reference index | ||
---|---|---|---|
Rating | |||
Option Adjusted Modified Duration (years) | |||
Maturity (years) | |||
Yield to Worst (%) | |||
Green Bonds (%) |
Date | Amount |
---|---|
Markets in the United States and globally soared in November. They responded to four consecutive weeks of positive vaccine news from four different pharmaceutical companies and the completion of the US presidential elections. The S&P 500 climbed 10.95%, its strongest return since April 2020. Value continued to outperform growth, with small-cap value posting the highest returns (up 19.3%), followed by mid caps (up more than 14%) and large caps (up 13.45%), as measured by their respective Russell value indices.
Name | Sector | Weight |
---|---|---|
Yes | No | N/A | ||
---|---|---|---|---|
Voting | ||||
Engagement | ||||
ESG integration | ||||
Exclusion |
Yes | No | N/A | ||
---|---|---|---|---|
Screening | ||||
Integration | ||||
Sustainability Themed Fund |
Investments are predominantly made in securities denominated in US dollars. The fund is denominated in euros. Derivatives are used to hedge currency to the euro.
In principle, this share class of the fund will distribute dividend.
For Robeco BP US Premium Equities, ESG factors are qualitatively considered on an individual basis in the fundamental analysis but are not structurally integrated in the investment process.
Robeco BP US Premium Equities (EUR) selects stocks based on their investment merit. Its bottom-up stock selection process is guided by a disciplined value approach, intensive internal research and risk aversion. The fund's broad definition of value looks beyond traditional value characteristics such as low Price/Earnings and Price/Book, and includes analysis of long-term business fundamentals and short term business momentum. The fund's investment objective is to participate in rising markets and preserve capital in falling markets through diligent risk management.
Risk management is fully integrated in the investment process to ensure that positions always meet predefined guidelines.
Currently, the US stock market is exhibiting traits of a ‘split personality’. On one hand, a rarified 90% of the stocks in the S&P 500 are trading above their 200-day moving averages. On the other, the stock markets' ‘fear index’, the VIX Index of implied stock market volatility, has remained above 20 for 196 consecutive trading days and has averaged a reading of 30+ this year, both marks not seen since the global financial crisis.One should expect volatility to remain elevated, with an ongoing ‘push-and-pull’ between valuation skepticism and uncertainty surrounding vaccine availability and administration, offset by the Fed's monetary stimulus ‘bazooka’ and record lax financial conditions. As always, the fund will continue to remain focused on a bottom-up approach, investing in companies exhibiting attractive valuation, strong fundamentals and improving momentum.
Mr. Ramallo is the senior portfolio manager for Boston Partners Premium Equity product. Previously, Mr. Ramallo was the assistant portfolio manager for the Small Cap Value products. Prior to his portfolio management role, Mr. Ramallo was a research analyst for Boston Partners. He joined the firm from Deloitte & Touche L.L.P., where he spent three years, most recently in their Los Angeles office. Mr. Ramallo holds a B.A. degree in economics/business from the University of California at Los Angeles and an M.B.A. from the Anderson Graduate School of Management at UCLA. He holds the Chartered Financial Analyst® designation. He is also a Certified Public Accountant (inactive). He has twenty years of investment experience.
Management company | |
Fund capital | |
Size of share class | |
Outstanding shares | |
ISIN | LU1208677333 |
Bloomberg | RUSIEHE LX |
Valoren | 27621970 |
WKN | A2DTH4 |
Availability | |
1st quotation date | 1427328000000 |
Close financial year | 31-12 |
Legal status | |
Tracking error limit (%) | |
Reference index |
Ongoing charges |
|
---|---|
This fund deducts ongoing charges of |
These charges comprise | ||
---|---|---|
Management fee | ||
Service fee |
Transaction costs |
|
---|---|
The expected transaction costs are |
Performance fee |
|
---|---|
This fund may also deduct a performance fee of |
max entry fee | ||
Max exit fee | ||
Max sub fee | ||
Max switch fee |
The fund is established in Luxembourg and is subject to the Luxembourg tax laws and regulations. The fund is not liable to pay any corporation, income, dividend or capital gains tax in Luxembourg. The fund is subject to an annual subscription tax ('tax d'abonnement') in Luxembourg, which amounts to 0.01% of the net asset value of the fund. This tax is included in the net asset value of the fund. The fund can in principle use the Luxembourg treaty network to partially recover any withholding tax on its income.
Investors who are not subject to (exempt from) Dutch corporate-income tax (e.g. pension funds) are not taxed on the achieved result. Investors who are subject to Dutch corporate-income tax can be taxed for the result achieved on their investment in the fund. Dutch bodies that are subject to corporate-income tax are obligated to declare interest and dividend income, as well as capital gains in their tax return. Investors residing outside the Netherlands are subject to their respective national tax regime applying to foreign investment funds. We advise individual investors to consult their financial or tax adviser about the tax consequences of an investment in this fund in their specific circumstances before deciding to invest in the fund.
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.
By clicking “I agree” you confirm that you/the company you represent falls under one of the above-mentioned categories of addressees and that you have read, understood and accept the terms of use for this website.